QAV 680

Drug Profile

QAV 680

Alternative Names: QAV680

Latest Information Update: 24 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Antiallergics
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Seasonal allergic rhinitis

Most Recent Events

  • 06 Jan 2011 Novartis completes a phase II trial in Seasonal allergic rhinitis in Canada
  • 16 Sep 2010 Suspended - Phase-II for Asthma in Germany (PO)
  • 16 Sep 2010 Suspended - Phase-II for Asthma in Russia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top